These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 33536184)
1. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. Weill A; Nguyen P; Labidi M; Cadier B; Passeri T; Duranteau L; Bernat AL; Yoldjian I; Fontanel S; Froelich S; Coste J BMJ; 2021 Feb; 372():n37. PubMed ID: 33536184 [TBL] [Abstract][Full Text] [Related]
2. Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma. Samarut E; Lugat A; Amelot A; Scharbarg E; Hadjadj S; Primot C; Loussouarn D; Thillays F; Buffenoir K; Cariou B; Drui D; Roualdes V J Neurooncol; 2021 Mar; 152(1):115-123. PubMed ID: 33392938 [TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas. Lee KS; Zhang JJY; Kirollos R; Santarius T; Nga VDW; Yeo TT Sci Rep; 2022 Feb; 12(1):1942. PubMed ID: 35121790 [TBL] [Abstract][Full Text] [Related]
4. Preliminary report of patients with meningiomas exposed to Cyproterone Acetate, Nomegestrol Acetate and Chlormadinone Acetate - Monocentric ongoing study on progestin related meningiomas. Devalckeneer A; Aboukais R; Bourgeois P; De Witte O; Racape J; Caron S; Perbet R; Maurage CA; Lejeune JP Clin Neurol Neurosurg; 2021 Nov; 210():106959. PubMed ID: 34592677 [TBL] [Abstract][Full Text] [Related]
5. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Gil M; Oliva B; Timoner J; Maciá MA; Bryant V; de Abajo FJ Br J Clin Pharmacol; 2011 Dec; 72(6):965-8. PubMed ID: 21627676 [TBL] [Abstract][Full Text] [Related]
6. Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Cebula H; Pham TQ; Boyer P; Froelich S Acta Neurochir (Wien); 2010 Nov; 152(11):1955-6. PubMed ID: 20811919 [No Abstract] [Full Text] [Related]
7. Probable Drug-Related Meningioma Detected During the Course of Medication Review Services. Alderman CP Consult Pharm; 2016 Sep; 31(9):500-4. PubMed ID: 27636874 [TBL] [Abstract][Full Text] [Related]
8. Risk of intracranial meningioma with three potent progestogens: A population-based case-control study. Hoisnard L; Laanani M; Passeri T; Duranteau L; Coste J; Zureik M; Froelich S; Weill A Eur J Neurol; 2022 Sep; 29(9):2801-2809. PubMed ID: 35621369 [TBL] [Abstract][Full Text] [Related]
9. Cyproterone acetate and risk of meningioma: a nationwide cohort study. Mikkelsen AP; Greiber IK; Scheller NM; Hilden M; Lidegaard Ø J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):222-223. PubMed ID: 34187864 [No Abstract] [Full Text] [Related]
10. [Cyproterone acetate and meningioma: The latest findings]. Schmutz JL Ann Dermatol Venereol; 2018 May; 145(5):390-391. PubMed ID: 29703641 [No Abstract] [Full Text] [Related]
11. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review. Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524 [TBL] [Abstract][Full Text] [Related]
12. Prolonged use of nomegestrol acetate and risk of intracranial meningioma: a population-based cohort study. Nguyen P; Roland N; Neumann A; Hoisnard L; Passeri T; Duranteau L; Coste J; Froelich S; Zureik M; Weill A Lancet Reg Health Eur; 2024 Jul; 42():100928. PubMed ID: 38800110 [TBL] [Abstract][Full Text] [Related]
13. Abrupt regression of a meningioma after discontinuation of cyproterone treatment. Gonçalves AM; Page P; Domigo V; Méder JF; Oppenheim C AJNR Am J Neuroradiol; 2010 Sep; 31(8):1504-5. PubMed ID: 20053802 [TBL] [Abstract][Full Text] [Related]
14. Estrogen and Progesterone Therapy and Meningiomas. Hage M; Plesa O; Lemaire I; Raffin Sanson ML Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34935947 [TBL] [Abstract][Full Text] [Related]
15. First case of cyproterone acetate induced multiple meningiomas in identical female twins: A case report. Batchinsky-Parrou V; Barraud S; Kleiber JC; Litre F Neurochirurgie; 2022 Apr; 68(3):323-326. PubMed ID: 33989640 [TBL] [Abstract][Full Text] [Related]
16. Use of progestogens and the risk of intracranial meningioma: national case-control study. Roland N; Neumann A; Hoisnard L; Duranteau L; Froelich S; Zureik M; Weill A BMJ; 2024 Mar; 384():e078078. PubMed ID: 38537944 [TBL] [Abstract][Full Text] [Related]
17. Hormonal therapies and meningioma: is there a link? Cea-Soriano L; Blenk T; Wallander MA; Rodríguez LA Cancer Epidemiol; 2012 Apr; 36(2):198-205. PubMed ID: 21943794 [TBL] [Abstract][Full Text] [Related]
18. Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization. Passeri T; Giammattei L; Le Van T; Abbritti R; Perrier A; Wong J; Bourneix C; Polivka M; Adle-Biassette H; Bernat AL; Masliah-Planchon J; Mandonnet E; Froelich S Acta Neurochir (Wien); 2022 Jan; 164(1):255-263. PubMed ID: 34613529 [TBL] [Abstract][Full Text] [Related]
19. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. Gazzeri R; Galarza M; Gazzeri G N Engl J Med; 2007 Dec; 357(23):2411-2. PubMed ID: 18057351 [No Abstract] [Full Text] [Related]
20. Cyproterone acetate and meningioma: a nationwide-wide population based study. Champeaux-Depond C; Weller J; Froelich S; Sartor A J Neurooncol; 2021 Jan; 151(2):331-338. PubMed ID: 33394263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]